We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01426893
First Posted: September 1, 2011
Last Update Posted: March 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled treatments. In real life, however, patients may make many errors with their usual inhalation device, which may negate the benefits observed in clinical trials. In real life, many errors seem to be made, but no wide-scale evaluation has been performed. The correct use of inhalation devices is essential to ensure the effectiveness of the treatment. It has been recently demonstrated that inhaler misuse is associated with decreased asthma control in asthmatics treated with an inhaled corticosteroid. The aim of our observational study was to evaluate the inhaler device usage in patients with asthma or chronic obstructive pulmonary disease (COPD).

Condition
Asthma, Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Investigator's evaluation of the correctness of patients' usage of inhaler device in patients with asthma or COPD assesses by investigator/pulmonologist [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Global assessment of disease control, done by investigator. Investigator will globally assess the disease control by one on three categories: 'fully controlled', 'partially controlled', 'uncontrolled'. [ Time Frame: 12 weeks ]
  • Evaluation of patients' perception of the inhaler device and their perspective of symptom control and impact on daily life, by using the patient's questionnaire [ Time Frame: 12 weeks ]
  • Evaluation of the influence of practical education of the patients (performed by physician and/or nursing staff) on all above parameters/assessments [ Time Frame: 12 weeks ]
  • Collection of local demographics data in patients with asthma or COPD [ Time Frame: 12 weeks ]

Enrollment: 310
Study Start Date: October 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
The inhaler device usage in patients with asthma or COPD

Detailed Description:
Observational study to evaluate the correctness of the use of inhaler device in patients with asthma or chronic obstruct
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Speciality care clinics
Criteria

Inclusion Criteria:

  • Provision of subject informed consent
  • Females or males aged > 18 years

Exclusion Criteria:

- If participating in any other clinical trial, the subject cannot take part in this study

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426893


Locations
Serbia
Research Site
Belgrade, Serbia
Research Site
Kragujevac, Serbia
Research Site
Nis, Serbia
Research Site
Sombor, Serbia
Research Site
Sremska Kamenica, Serbia
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Predrag Rebic, Prof.dr Clinical Center of Serbia, Belgrade
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01426893     History of Changes
Other Study ID Numbers: NIS-RRS-XXX-2011/1
First Submitted: August 29, 2011
First Posted: September 1, 2011
Last Update Posted: March 29, 2012
Last Verified: March 2012

Keywords provided by AstraZeneca:
Respiratory disease
COPD

Additional relevant MeSH terms:
Asthma
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases